Company ProfilePremium

Sihuan Pharmaceutical Holdings Group Ltd.

Company Profile Analysis

Ticker: 0460.HK

ESOMAR 23 Corporate BadgeISO Certifications Badge
Sihuan Pharmaceutical Holdings Group Ltd. - Company showcase

Year Founded & Workforce

2001

2,843 Employees

Sihuan Pharmaceutical Holdings Group Ltd. logo

Sihuan Pharmaceutical Holdings Group Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Sihuan Pharmaceutical Holdings Group Ltd. Overview

Sihuan Pharmaceutical is a Hong Kong-listed, Bermuda-incorporated Chinese healthcare group that has spent a decade migrating from a policy-exposed cardio-cerebrovascular (CCV) generic drug franchise toward a "medical aesthetics + innovative drugs" dual-engine model. Its Meiyan Space platform sells the Hugel-manufactured botulinum toxin Letybo® and a growing portfolio of self-developed regenerative fillers (PLLA, PCL), hyaluronic-acid products, skin boosters and the Sylfirm X RF-microneedle device, and since FY2025 has been the group's largest revenue and profit contributor. Its innovative-drug arm comprises Xuanzhu Biopharm (2575.HK, spun off October 2025; oncology and digestive drugs) and Huisheng Biopharm (diabetes and GLP-1). A legacy portfolio of roughly 100 generic drugs, battered by volume-based procurement (VBP), is being harvested and divested. After four loss-making years, the group returned to profit in FY2025, carries a large net cash position, and trades at a modest valuation reflecting execution, governance and policy risk.


Company's own description (FY2025 Annual Results, 31 Mar 2026)

The company frames 2025 as the year it moved from a "transformation and investment period" into a "value realisation period," built around a "dual-wheel drive" of medical aesthetics and innovative drugs, with generic medicines positioned as a "cash cow." The segment note defines three reportable segments: (a) medical aesthetic products, providing non-invasive or minimally invasive aesthetic solutions spanning filling, shaping, supporting, supplementing, optoelectronic devices, body sculpting and skin care; (b) innovative medicine and other medicine; and (c) generic medicine. The stated vision is to become a leading medical aesthetics and biopharmaceutical company in China, with the 2026 plan opening a three-year strategic cycle aimed at making Sihuan a benchmark enterprise in China's medical aesthetics industry.

Business model and revenue model

Revenue model elementFY2025 relevanceSource
Product sales — medical aesthetic productsRMB1,485.3m (56.7% of revenue)FY2025 Results
Product sales — innovative and other medicineRMB176.4m (6.7%)FY2025 Results
Product sales — generic medicineRMB956.3m (36.5%)FY2025 Results
In-licensed distribution (agency)Letybo® (Hugel) and Persnica™ HA (Hugel) sold under exclusive China rights; CELLBOOSTER® (Suisselle) under permanent China agencyFY2025 Results; HKEX 27 Sep 2024
Out-licensing (upfront/milestones/royalties)Bireociclib EAEU licence; Boston Oncology MENA licence (H1 2026, >US$100m potential)FY2025 and 2026 Interim Results
Commercialisation partnershipsHui You Jing via Huadong Medicine; Hui You Jia/Hui You Da via Tonghua DongbaoFY2025 and 2026 Interim Results
Device + consumablesSylfirm X device placements with recurring consumables2026 Interim Results

All reported revenue is recognised from product sales at a point in time (FY2025 revenue note). There is no material subscription, service or royalty revenue in reported turnover; licensing income from out-licensing deals and hospital services are booked in "other income" (hospital services income RMB62.0m in FY2025; R&D income RMB13.2m; distribution-rights sales RMB2.8m).

Value-chain position

Sihuan is vertically integrated in its pharmaceutical businesses (R&D, API/formulation manufacturing, regulatory, commercialisation) and operates a hybrid model in aesthetics: in-licensed hero products (Letybo®, manufactured by Hugel in Korea) used as "traffic drivers," combined with self-developed, higher-margin regenerative products manufactured in-house. Meiyan Space reports three production bases globally (HKEX announcement, 30 Sep 2025). Huisheng Biopharm operates biologics capacity of approximately 25 million units annually, with Phase II capacity of approximately 100 million units planned (2026 Interim Results).

Customers and end-markets

Customer typeDescriptionEvidence
Medical aesthetics institutionsMore than 9,000 cooperating institutions across 34 provinces and 370+ cities; all industry top-500 institutions covered; 1,500 key core hospitals2026 Interim Results
Leading aesthetic chainsDeep partnerships with Mylike and Yestar; 25% of leading chain institutions contribute 75% of Letybo® salesFY2025 Results
Distributors / pharmaceutical commercial companiesPrimary customers for innovative and generic drugs (Xuanzhu had over 105 distributors at IPO)Xuanzhu IPO data (etnet)
Hospitals (via distributors)Anaprazole in nearly 2,500 institutions; Bireociclib 500+ hospitals; Hui You Jing 7,000+ hospitals via Huadong2026 Interim Results
Licensing partnersHuadong Medicine, Tonghua Dongbao, Boston Oncology, partners in 15 countries for Huisheng2026 Interim Results

Customer concentration (material): a single customer group accounted for approximately RMB728.5m of FY2025 revenue (27.8% of total; FY2024: RMB173.6m), and RMB173.6m in H1 2026 (vs RMB213.6m in H1 2025), across the medical aesthetics and generic segments (FY2025 and 2026 Interim Results).

Independent characterisation

Sihuan is best understood as a holding company of three businesses with very different economics: (1) a high-margin, consumer-discretionary aesthetics distributor-turned-brand-owner that now generates most of group profit (FY2025 segment gross margin 79.5%, segment profit margin 55.1%); (2) a cash-consuming innovative drug portfolio that just crossed into small segment profit in H1 2026, partly helped by licensing; and (3) a structurally declining generic franchise that swung to a segment loss in H1 2026. Reported group earnings are therefore highly sensitive to mix, to one-off disposal gains, to the minority-interest split in partly owned subsidiaries, and to a punitive effective tax rate (55.6% in FY2025) caused by unrecognised losses at loss-making subsidiaries.

Strategy

Stated strategy (FY2025 Annual Results; 2026 Interim Results)

The core framing is a "medical aesthetics + innovative drugs" dual-engine drive. The 2026 interim report describes a layered model: medical aesthetics as the primary growth pillar, innovative drugs as the second growth curve, generics as a cash-flow ballast, and gradual divestment of generic and non-core assets. For 2026, management set the theme of deepening the dual-wheel drive, unleashing synergies, expanding globally and improving capital efficiency, across five directions: compliance, product, technology, globalisation and industry-chain integration.

Strategic initiatives (last 24 months)

InitiativeDetailTimingSource
Full-category compliant aesthetics portfolioToxin + HA + regenerative + optoelectronic + boosters; company claims to be the only firm with fully compliant coverage of all non-invasive categories2,025FY2025 Results
Medical aesthetics R&D reallocationRaise medical aesthetics to 60% of total R&D budget over three years; focus on regenerative materials, recombinant collagen, weight-loss aesthetics, high-end boosters2026–2028FY2025 Results
Channel targetsCover 8,500 compliant institutions (already exceeded 9,000 by H1 2026); KA team; public-hospital team; "Spark Plan" for lower tiers; "One Hospital, One Policy"2,026FY2025 and 2026 Interim Results
Marketing 3.0Omni-channel marketing; Meituan 618 campaign generated GMV of RMB22m; Xiaohongshu seeding2025–20262026 Interim Results
AI-driven R&DAI aesthetics R&D platform co-built with dProtein (Beijing Shenyuanzhi); AI antibody collaboration with Biocytogen; Xuanzhu AI drug design, TCE and oligonucleotide platforms2025–20262026 Interim Results; Biocytogen release
GlobalisationSuisselle investment; Korean subsidiary; US R&D base; EU registrations; expansion into Southeast Asia and Latin America2025–2026FY2025 and 2026 Interim Results
Capitalisation of subsidiariesXuanzhu IPO completed; Huisheng "continues to advance its capitalisation process" (possible future listing)2025 onwardFY2025 Results
Minority buy-in at Meiyan SpaceRaised to 90%; intention to acquire remaining interestH1 2026 onward2026 Interim Results
Generic divestmentOrderly divestment of underperforming generic and non-core assetsOngoingFY2025 and 2026 Interim Results
Shareholder returnsBuybacks (HK$500m programme announced Oct 2024; 46m shares repurchased H1 2026); employee share award scheme; dividends resumed2024–2026HKEX announcements

Medium-term targets and guidance

No quantitative revenue, margin or earnings guidance has been published. Qualitative targets include: annual launch of new aesthetics products; Semaglutide diabetes approval in early 2027 and an obesity NDA in Q4 2026; Dirozalkib NRDL inclusion in 2026; and Huisheng "significant growth within the next five years" (FY2025 Results). ESG/sustainability targets are not disclosed in the sources reviewed.

Products & Services

Medical aesthetics (Meiyan Space / Meifu Space)

ProductCategoryDescription / specificationsOriginApproval / launchPositioning / targetSource
Letybo®Botulinum toxin type A900kDa complex, 99.5% purity; 50U and 100U; near-neutral pH; indications include dynamic wrinkles, facial contouring, leg/shoulder slimming. 2025 sales exceeded 1.2m vials (+50%+); 8,000+ institutionsIn-licensed from Hugel (Korea); exclusive China partnerNMPA approval 2020; launch 2021; registration renewed to end-2030"Light-luxury" price band between imported premium and domestic value toxins; channel traffic driverFY2025 Results; HKEX 27 Sep 2024
HuiyanzhenPLLA regenerative fillerPoly-L-lactic acid microspheres for moderate-to-severe nasolabial folds; shallow collagen regeneration and maintenanceSelf-developedApproved Apr 2025; launched Jul 2025; six additional specs approved Jan 2026 (45–150mg range)Mid-to-high end; cross-sell with full categoryFY2025 and 2026 Interim Results
SifuyanPLLA regenerative filler (large particle)Deep facial volumetric fillingSelf-developedApproved Apr 2025; launched Jul 2025High-net-worth clients at premium institutions; key 2026 priority2026 Interim Results
QingyanPCL regenerative fillerPolycaprolactone microspheres in gel carrier; pre-filled syringe; immediate fill plus collagen stimulation; effect over one yearGroup product (origin not specified)Approved Mar 2025; launched Jul 2025Mid-face lifting; high-end anti-ageing coursesFY2025 and 2026 Interim Results
DongyanSkin booster / rejuvenating serumComposite solution: sodium hyaluronate, L-carnosine, vitamin B2, collagen amino acids; first approved L-carnosine composite booster for direct facial useSelf-developedApproved Sep 2025; launched Nov 2025; 1,000+ institutions by H1 2026Traffic SKU for new-customer acquisitionFY2025 and 2026 Interim Results
Persnica™High-G HA fillerBone-support contour sculpting; sold only as part of combination therapy, not retailed aloneIn-licensed (Hugel)—Accompanying product in "contour fixation" courses2026 Interim Results; HKEX 27 Sep 2024
CELLBOOSTER®Skin boosterSwiss brand Suisselle; permanent China agency right via strategic shareholdingIn-licensed (Suisselle)China status not disclosedExpands booster pipelineFY2025 Results
Sylfirm XDual-wave RF microneedleContinuous plus pulsed wave; bipolar non-insulated electrodes; indications include tightening, acne scars, melasma, hair regrowth; US FDA and Korea KFDA certifiedIn-licensed/distributed (Korean origin; licensor not named in sources)Nationwide rollout 2025"Basal anti-ageing"; 25–40 age group; ~400 institutions, 100,000+ consumers by Jun 2026FY2025 and 2026 Interim Results
Combination protocolsService bundles"Letybo+", "Magic Youthful Face", "contour fixation + advanced anti-ageing", "Sylfirm X+ Plan"Proprietary marketing2025–2026Raise ticket size and loyaltyFY2025 and 2026 Interim Results
Semaglutide (weight-loss indication)GLP-1Greater China clinical and commercial rights for the obesity indication licensed to Meiyan Space (2024)Huisheng-developedNDA expected Q4 2026Weight-management aesthetics2026 Interim Results

Medical aesthetics pipeline (cut-off 31 Jul 2026, 2026 Interim Results): novel regenerative materials (CaHA, PHA etc.) — 4 self-developed plus 2 jointly invested; collagen/silk fibroin (animal, recombinant humanised, recombinant human) — 8 self-developed plus 2 exclusively distributed; HA super boosters (PDRN and composites) — 4 self-developed plus 2 exclusive; HA composites/fillers — 7 self-developed; devices — facial and body ultrasound (2 exclusive), cryolipolysis (1 exclusive), Thermage-type (1 exclusive), fat harvesting system (1 acquired); GLP-1 (1 self-developed). Management cites 40+ candidates on five proprietary technology platforms with 20+ in clinical trials, plus a first-in-class PHA regenerative material. Two high-end composite skin boosters have completed filing dossiers. Meiyan reported over 30 approved products as of Sep 2025 (HKEX, 30 Sep 2025). Pricing is not publicly disclosed for any aesthetics product.

Innovative medicine — Xuanzhu Biopharm (2575.HK)

Product / candidateTarget / classIndication(s)Status (31 Jul 2026)Commercial dataSource
Xuan Yue Ning (Bireociclib)CDK2/4/6 inhibitor, small molecule, in-houseHR+/HER2- advanced breast cancer: later-line monotherapy; 2L with fulvestrant; 1L with AIApproved May 2025 (two indications); 1L approved Mar 2026; NRDL Dec 2025; adjuvant early BC in development500+ hospitals; 140+ sales staff; 200+ DTP pharmacies; BRIGHT-2 final mPFS 17.5 vs 7.3 months (HR 0.47, JAMA Oncology)FY2025 and 2026 Interim Results
Xuan Fei Ning (Dirozalkib)ALK inhibitor, in-house1L ALK+ advanced NSCLC; adjuvant in developmentApproved Aug 2025; NRDL targeted for 2026~200 hospitals (end-2025); DIAMOND-2 mPFS 31.3 vs 12.9 months (HR 0.47), IC-ORR 91.7%FY2025 and 2026 Interim Results
An Jiu Wei (Anaprazole Sodium)Novel PPI, in-house, global IPDuodenal ulcer (approved); reflux esophagitis (NDA accepted); H. pylori eradication (Ph III started)Approved Jun 2023; NRDL renewed 2025 at unchanged priceNearly 2,500 institutions; 90+ distributorsFY2025 and 2026 Interim Results
KM602CD80 fusion protein (acquired)Solid tumours (melanoma etc.)Clinical—Pipeline tables
KM501HER2/HER2 biparatopic ADC (in-house)HER2+ and HER2-low solid tumoursClinical—Pipeline tables
XZP-7797PARP1-selective inhibitorSolid tumours incl. brain metastasesIND Feb 2025; Ph I from Dec 2025Partnering talks (US/EU/Japan/Korea)FY2025 Results
XZP-6924USP1 inhibitorSolid tumoursEarly clinical/IND—Pipeline tables
XZB-0004AXL inhibitor (licensed-in)Solid tumours; MDS/AMLClinical—Pipeline tables
XZP-6877DNA-PK inhibitorSolid tumoursEarly—Pipeline tables
NG-350ACD40-expressing oncolytic virus (licensed-in)Solid tumours; LARC (pMMR)US FDA Fast Track—FY2025 Results
XZP-P607ENPP3/CD3 bispecific (TCE)Renal, lung, endometrial cancerPreclinical (new in 2026)—2026 Interim Results
XZP-P608KLK5/7–IL4R bispecificAtopic dermatitisPreclinical (new in 2026)—2026 Interim Results
XZP-5610FXR agonistNASHClinical—Pipeline tables
XZP-6019KHK inhibitorNASHEarly—Pipeline tables

At IPO (Sep 2025), Xuanzhu reported 15 issued China patents and 28 issued patents in the US and other jurisdictions (etnet IPO data).

Innovative and other medicine — Huisheng Biopharm

ProductClassStatusCommercial notesSource
Hui You Jing (ganagliflozin proline tablets)Class 1 SGLT-2 inhibitor; also + metforminApproved Jan 2024; NRDL 2024Exclusive Greater China promotion by Huadong Medicine; 7,000+ hospitalsFY2025 and 2026 Interim Results
Hui You Jia (insulin degludec/insulin aspart 70/30)First domestic biosimilarApproved Jul 2024Exclusive mainland commercialisation by Tonghua Dongbao (from 14 Feb 2026); nearly 6,000 hospitalsFY2025 and 2026 Interim Results
Hui You Da (insulin degludec)First domestic biosimilar; ~42h actionApproved Aug 2024Tonghua Dongbao; nearly 900 hospitals; ANVISA (Brazil) GMP certificationFY2025 and 2026 Interim Results
Hui You Rui / Rui 30 / Rui 50Insulin aspart and premixesMarketed—Pipeline tables
Semaglutide injection (diabetes)GLP-1 RA biosimilarNDA accepted Aug 2025; passed NMPA on-site inspection; approval expected early 2027—2026 Interim Results
Semaglutide injection (obesity)GLP-1 RAPh III complete; NDA expected Q4 2026Greater China rights licensed to Meiyan Space2026 Interim Results
P052GLP-1R/GCGR dual agonistIND approvedT2D and obesityFY2025 Results
HSP002Once-weekly insulinDevelopment—Pipeline tables
Insulin degludec/liraglutideCombinationDevelopment—Pipeline tables
Ganagliflozin/metformin XRCombinationDevelopment—Pipeline tables
Empagliflozin, DapagliflozinSGLT-2 genericsDapagliflozin approved 2025—FY2025 Results
Sitagliptin (±metformin), Vildagliptin, LinagliptinDPP-4 genericsMarketed/approved—Pipeline tables
RepaglinideGlinideApproved H1 2026 (consistency-evaluated)—2026 Interim Results
Mecobalamin (tab/inj), Thioctic acid inj., Calcium dobesilate, EpalrestatDiabetic complicationsMarketed—Pipeline tables

As of 31 Jul 2026, Huisheng had 18 approved varieties (27 specifications, 29 marketing approvals) (2026 Interim Results).

Generic medicine (selected)

PeriodNew approvals / consistency evaluationsSource
FY202511 new products: Sugammadex Sodium Inj., Aspirin EC Tablets, Zoledronic Acid Inj., Duloxetine EC Capsules, Metaraminol Inj., Etomidate MCT/LCT Emulsion, Nicorandil Inj., Levetiracetam Oral Solution, Phloroglucinol Inj., Dipyridamole Tablets, Milrinone Inj. New strengths: Citicoline Sodium Inj., Sacubitril Valsartan Tablets. Consistency evaluation passed: Ornidazole Inj., Edaravone Inj., Nicorandil TabletsFY2025 Results
H1 20268 approvals, all consistency-evaluated: Pentoxifylline Inj. and SR Tablets, Tirofiban/NaCl Inj., Cefazolin dual-chamber bag, Lopinavir/Ritonavir Tablets (only four domestic approvals), Tedizolid Phosphate for Inj., Vortioxetine Tablets, Cisatracurium Inj.2026 Interim Results

The group holds approvals for nearly 100 generic products in CCV, anti-infective and neurology (FY2025 Results). Historic franchise brands include Kelinao (cinepazide maleate), Anjieli, Chuanqing, Qu'Ao, Aogan, GM1, Oudimei, Yuanzhijiu, Yeduojia and Guhong (Annual Reports 2010–2014); their current revenue contribution is not disclosed.

Financial Narrative

Income statement

Company-reported operating profit was RMB607.1m in FY2025 and a loss of RMB138.1m in FY2024 (FY2025 Results); the gap versus S&P EBIT reflects other income (RMB200.5m) and other gains (RMB60.5m) included by the company. FY2025 DPS comprises an interim dividend of RMB0.99 cents and a final of RMB0.96 cents. FY2024 DPS is the RMB1.90-cent interim (no final). FY2021 company-reported revenue from continuing operations was RMB3,291.3m before later restatement; the S&P figure of RMB3,038m reflects restatement for discontinued operations (FY2021 Results vs S&P).

Margins and growth (%)

Revenue CAGR (derived): FY2021–FY2025 is -3.7% per year; FY2022–FY2025 is +6.3% per year; FY2023–FY2025 is +18.6% per year.

Balance sheet

Negative net debt denotes net cash. Company-reported intangible assets at 31 Dec 2025 were RMB953.8m (deferred development costs RMB518.1m plus product development in progress RMB408.3m), versus S&P's RMB435.6m; S&P appears to reclassify capitalised development costs to long-term deferred charges (RMB518.1m). Company-reported aggregate cash, wealth-management products, pledged and time deposits were RMB4,397.4m (31 Dec 2025) and RMB4,018.2m (30 Jun 2026).

Off-balance-sheet-like obligations: "redemption liabilities on subsidiaries' shares" — repurchase obligations to third-party investors in subsidiaries — generated interest expense of RMB161.8m in FY2025 and RMB228.8m in FY2024 (FY2025 Results). Xuanzhu-related obligations were released at its October 2025 listing, cutting H1 2026 redemption interest to RMB52.9m from RMB87.0m (2026 Interim Results). Remaining obligations (largely Huisheng-related, inferred) were not quantified separately in sources reviewed. Other non-current liabilities fell from RMB1,346.6m to RMB134.9m in FY2025, consistent with the Xuanzhu release.

Cash flow

TTM to 30 Jun 2026: operating cash flow RMB-20.5m; free cash flow RMB-98.7m (S&P).

Ratios (derived from tables above; year-end basis)

ROIC (S&P, TTM Aug 2026) was 5.4% and WACC 9.2% (StockAnalysis). Net debt to EBITDA is negative because of net cash and is meaningless where EBITDA is negative (blank). Cash conversion cycle is not disclosed; the company reported inventory turnover of 221 days for H1 2026 (206 days in H1 2025), and trade receivables are on 90–180 day terms (FY2025 Results). Interest coverage is depressed by non-cash redemption-liability interest.

Commentary on trends, inflections and drivers

Revenue. The FY2021–FY2023 collapse (-39% cumulative) was policy-driven: VBP price cuts and the inclusion of key products in the national key monitoring catalogue crushed the CCV generic franchise, while carve-outs moved businesses into discontinued operations. FY2024 was the trough (+2.2%). FY2025's +37.7% was almost entirely medical aesthetics (+RMB741.1m) partly offset by generics (-RMB143.0m). H1 2026 growth stalled at +1.3% as a RMB296.2m generic decline offset aesthetics (+RMB108.0m) and innovative (+RMB203.2m) gains.

Profitability. Gross margin is mix-driven: it peaked at 80.0% in FY2021 when branded CCV generics dominated, fell with VBP, then recovered to 68.8% in FY2025 on aesthetics (segment gross margin 79.5%). H1 2026 gross margin dropped to 58.7% from 66.1% due to generic list-price adjustments, signalling that generic gross margin has compressed severely. Operating leverage is visible in falling R&D (from RMB936.6m in FY2022 to RMB291.3m in FY2025) as core pipeline assets reached approval and Xuanzhu began to self-fund.

Earnings quality. FY2025 profit before tax of RMB417.2m was achieved despite RMB201.6m of finance costs (80% redemption-liability interest) and a 55.6% tax rate. H1 2026 profit was flattered by a RMB154.2m subsidiary-disposal gain and a RMB110.7m share of associate profit, partly offset by a RMB64.2m impairment of equity-accounted investments. Excluding the disposal gain and associate profit, H1 2026 pre-tax profit would have been roughly RMB101m (derived), well below the RMB156.9m in H1 2025.

Cash generation. The deterioration in operating cash flow to RMB-23.6m in FY2025 despite a return to profit is the most important analytical red flag. Accounts receivable nearly doubled (RMB594m to RMB1,156m) and trade and other receivables rose a further 22.3% to RMB2,372.0m by Jun 2026, including RMB259.9m of loans to third parties and RMB170.1m of loans to associates. Combined with the 27.8% single-customer concentration, this suggests growth is being financed on extended credit to large channel partners.

Balance sheet. Net cash of approximately RMB3.0bn (FY2025) and borrowings-to-equity of 14.9% (Jun 2026) give ample liquidity. All bank borrowings are secured and RMB-denominated (rates 2.55–4.00%). Equity attributable rose RMB1.48bn in FY2025, largely through reserves movements from the Xuanzhu listing (reserves swung from RMB-31.4m to RMB1,531.1m).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsKey operating entities

Medical aesthetic products

Botulinum toxin, regenerative fillers (PLLA, PCL), HA fillers, skin boosters, optoelectronic devices, body sculpting, skin care

Meiyan Space Biotechnology (Jilin) Co., Ltd. (90% owned after H1 2026); Beijing Meifu Space Medical Equipment Co., Ltd.

Innovative medicine and other medicine

Innovative oncology, digestive, NASH drugs; diabetes/metabolic drugs; biosimilar insulins

Xuanzhu Biopharmaceutical Co., Ltd. (2575.HK, non-wholly owned); Huisheng Biopharmaceutical Co., Ltd. (non-wholly owned)

Generic medicine

Nearly 100 generic products: CCV, anti-infective, neurology and others

Legacy Sihuan manufacturing subsidiaries

Segment revenue (CNY Mn)

Segment revenue (CNY Mn)FY2022FY2023FY2024FY2025

Medical aesthetic products

149.8449.9744.21,485.3

Innovative medicine and other medicine

60.9—57.6176.4

Generic medicine

—1,398.81,099.3956.3

Group total

2,1811,860.51,901.12,618.0

Revenue by Segment

Segment result (CNY Mn)FY2023FY2024FY2025

Medical aesthetic products

90251.0818.4

Innovative medicine and other medicine

—-948.0-648.0

Generic medicine

—356.5282.6

Total segment results

—-340.5453.0

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment Margins & Growth (%) and Revenue by Segment (%)

Metric (%)FY2024FY2025

Medical aesthetics segment margin

33.755.1

Innovative segment margin

-1,645.8-367.3

Generic segment margin

32.429.6

Medical aesthetics share of revenue

39.156.7

Innovative share of revenue

3.06.7

Generic share of revenue

57.836.5

Medical aesthetics revenue growth

65.499.6

Innovative revenue growth

—206.3

Generic revenue growth

-21.4-13.0

Revenue by Segment (Half-Yearly)

Segment metric (CNY Mn)H1 2025H1 2026

Medical aesthetics revenue

585.2693.3

Innovative and other revenue

58.2261.4

Generic revenue

502.7206.5

Medical aesthetics segment result

309.5343.2

Innovative and other segment result

-274.328.4

Generic segment result

168.4-74.1

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (CNY Mn)

3,0382,1811,8611,9012,618

Revenue growth (%)

23.3-28.2-14.72.237.7

Gross profit (CNY Mn)

2,4301,4881,2961,2421,802

SG&A (CNY Mn)

1,1291,0239111,1751,118

R&D expense (CNY Mn)

868.1936.6577.7473.9291.3

Operating income S&P EBIT (CNY Mn)

676.2-536.1-140.5-389.4476.7

EBITDA S&P (CNY Mn)

931.7-229.340.2-189.3642.6

Interest expense (CNY Mn)

117.4211.2269.3274.9201.6

Pre-tax income (CNY Mn)

496.0-2,123-161.3-428.3417.2

Income tax (CNY Mn)

253.1196.896.443.3231.8

Net income incl minorities (CNY Mn)

232.8-2,283-257.7-471.5185.4

Net income attributable (CNY Mn)

416.5-1,915-54.0-216.7179.7

EPS basic (MYR Bn)

0.0442-0.2052-0.0058-0.02340.0197

EPS diluted (MYR Bn)

0.0439-0.2052-0.0058-0.02340.0197

Dividend per share (MYR Bn)

0.0130.033—0.0190.0195

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

80.068.269.665.368.8

Operating margin S&P (%)

22.3-24.6-7.6-20.518.2

EBITDA margin (%)

30.7-10.52.2-10.024.5

Pre-tax margin (%)

16.3-97.3-8.7-22.515.9

Net margin attributable (%)

13.7-87.8-2.9-11.46.9

R&D intensity (%)

28.642.931.024.911.1

Effective tax rate (%)

51.0———55.6

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (CNY Mn)

14,49612,14111,53510,53211,632

Cash and equivalents (CNY Mn)

5,6823,8293,7793,5223,561

Cash plus short-term investments (CNY Mn)

5,7924,7924,4983,7773,977

Short-term debt incl current LTD (CNY Mn)

200341270169217

Long-term debt (CNY Mn)

845849905714695

Total debt incl leases (CNY Mn)

1,0811,2911,251943972

Net debt (CNY Mn)

-4,710-3,501-3,246-2,834-3,006

Total equity (CNY Mn)

9,1505,6405,1374,9496,900

Equity attributable to owners (CNY Mn)

8,2844,7374,4324,3725,849

Minority interests (CNY Mn)

8669037055771,051

Goodwill (CNY Mn)

14.21.91.91.91.9

Other intangibles S&P (CNY Mn)

445.8594.1655.5598.8435.6

Working capital (CNY Mn)

5,2404,0172,0972,4072,963

Accounts receivable (CNY Mn)

7795223985941,156

Inventory (CNY Mn)

715607557417618

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (CNY Mn)

665.346.5199.5276.1-23.6

Capital expenditure (CNY Mn)

-601.0-402.5-125.4-70.7-58.4

Free cash flow (CNY Mn)

64.3-356.074.1205.4-81.9

Purchase of intangibles (CNY Mn)

-124.6-187.5-170.0-109.1-136.2

Dividends paid (CNY Mn)

-122.9-130.6-298.6-177.1-90.9

Share buybacks (CNY Mn)

-206.40-33.8-20.3-188.6

Change in working capital (CNY Mn)

-246.5145.4111.118.7-579.5

Stock-based compensation (CNY Mn)

59.489.789.1418.09.0

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE attributable on year-end equity (%)

5.0-40.4-1.2-5.03.1

ROA (%)

1.6-18.8-2.2-4.51.6

Current ratio (x)

3.092.591.511.731.80

Debt to equity (x)

0.120.230.240.190.14

Interest coverage EBIT over interest (x)

5.8-2.5-0.5-1.42.4

Asset turnover (x)

0.210.180.160.180.23

Net debt to EBITDA (x)

-5.1—-80.7—-4.7

Region revenue (CNY Mn)

Region revenue (CNY Mn)FY2024FY2025

Chinese mainland

1,888.52,604.6

United States

12.613.1

Others

00.3

Total

1,901.12,618.0

Segment (FY2025 CNY Mn) Overview

Segment (FY2025 CNY Mn)Chinese mainlandUnited StatesOthersTotal

Medical aesthetics

1,472.213.101,485.3

Innovative and other

176.400176.4

Generic

956.000.3956.3

Region growth (%)

Region growth (%)FY2025H1 2026

Chinese mainland

37.91.5

United States

4.3-34.3

Share Price & Returns

Reference pointPrice (HKD)Source

15 Oct 2025 (repurchase average)

1.5189

HKEX 15 Oct 2025

31 Jul 2026

0.90

StockAnalysis

14 Aug 2026

0.86

StockAnalysis

27 Aug 2026 (repurchase average)

0.8111

Tiger Brokers

2 Oct 2026

0.72

StockAnalysis

Valuation Multiples

MultipleSihuan, 14 Aug 2026 (StockAnalysis)Sihuan, 2 Oct 2026 (derived)

Market cap (HKD Bn)

7.76

approx. 6.5

P/E trailing (x)

39.2

approx. 19 (on TTM attributable profit RMB301.8m)

P/E forward (x)

9.2—

P/S (x)

2.66

approx. 2.2

P/B (x)

1.01

approx. 0.93 (on Jun 2026 attributable equity RMB6,149m)

EV/Sales (x)

1.92—

EV/EBITDA (x)

7.4—

Per-Share Data and Dividends & Capital Returns

MetricFY2021FY2022FY2023FY2024FY2025

DPS declared (MYR Bn)

0.0130.033—0.0190.0195

Cash dividends paid (CNY Mn)

122.9130.6298.6177.190.9

Balance Sheet (31 Dec 2025–30 Jun 2026)

Bank borrowings maturity (CNY Mn)31 Dec 202530 Jun 2026

Within one year

192.3322.2

Two to five years

383.6279.1

Beyond five years

310.8280.6

Total bank borrowings

886.8881.9

Analyst Conclusions

Management guidance

No numerical guidance. Qualitative priorities for H2 2026–2027: grow high-end regenerative and skin-booster sales (Sifuyan + Qingyan combinations; review of two high-end boosters); complete acquisition of the remaining Meiyan Space equity; obtain semaglutide diabetes approval (early 2027) and file the obesity NDA (Q4 2026); secure Dirozalkib NRDL inclusion (2026); expand overseas licensing; continue generic divestments; and sustain buybacks.

Consensus expectations

Consensus is thin. The forward P/E of 9.2x at HK$0.86 (StockAnalysis) implies forward earnings expectations near HK$0.09bn above the current trailing level; this should be treated as a single-analyst estimate.

Bull case

  1. Aesthetics compounding with margin expansion: a full-category compliant portfolio already earning a 55% segment margin, with self-developed regenerative products growing in a weak market, could sustain double-digit growth as competitors retrench.

  2. Sum-of-the-parts discount: with group market cap near HK$6.5bn, net cash around RMB3.1bn and a listed Xuanzhu stake (Xuanzhu itself valued at approx. HK$4.6bn at HK$8.88 on ~518m shares), the aesthetics business may be implied at a low multiple.

  3. Self-help catalysts: Meiyan buy-in, falling R&D, lower redemption interest, generic exit and semaglutide launch could lift attributable profit and normalise the 55% tax rate.

Bear case

  1. Growth stall: aesthetics growth slowed to 18.5% just as Imeik and Huadong launched toxins; Letybo® pricing could come under pressure.

  2. Cash-flow quality: profits have not converted to cash (FY2025 OCF negative; receivables up 95%; 27.8% single-customer exposure), raising channel-stuffing or credit-risk concerns.

  3. Generic drag and one-offs: generics are now loss-making and H1 2026 profit relied on non-recurring gains; underlying pre-tax profit may have declined year on year.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timing
Semaglutide obesity NDA submissionQ4 2026
Dirozalkib NRDL negotiation resultLate 2026
Semaglutide diabetes approvalEarly 2027
FY2026 results (aesthetics growth, OCF, receivables, tax rate)Around March 2027
Remaining Meiyan Space buy-in termsUnspecified
Further generic disposals and receivable collection (RMB136.1m)Ongoing
Huisheng capitalisation / listing plansUnspecified
Customer concentration trendEach results release
Competitive response to new toxin approvalsOngoing

Analyst verdict

Sihuan Pharmaceutical has executed one of the more credible strategic pivots among Hong Kong-listed Chinese mid-cap pharma companies. Starting from a CCV generic franchise that lost most of its economic value to VBP and the 2019 key monitoring catalogue, management built a medical aesthetics business that in FY2025 produced RMB818m of segment profit, took meaningful share in a contracting market, and pushed the group back to profit after four loss-making years. It simultaneously crystallised the innovative-drug portfolio through the Xuanzhu IPO, removed the costliest redemption liabilities, and now holds a net cash position equal to roughly half its market capitalisation.

The market's scepticism — shares down about 53% since the October 2025 repurchase — is nonetheless understandable. The FY2025 turnaround did not convert into operating cash flow; receivables nearly doubled, and more than a quarter of revenue came from a single customer group. H1 2026 showed aesthetics growth decelerating to 18.5%, generics swinging to a loss and earnings supported by disposal gains. Competition in botulinum toxins intensifies in 2026, and Sihuan's flagship toxin remains an in-licensed product. Governance history and a founder-dominated board add a persistent discount.

On balance, the investment case is a "show-me" story with asymmetric optionality: the valuation (around 0.9x book and a low implied value for aesthetics after netting cash and the Xuanzhu stake) prices in substantial disappointment, while the next 12 months bring identifiable catalysts in GLP-1 approvals, NRDL access, minority buy-ins and generic exits. The decisive variables are cash conversion and aesthetics growth durability. If FY2026 shows positive operating cash flow, stable customer concentration and aesthetics growth above 15%, a re-rating is plausible. If receivables keep outpacing revenue, the discount is warranted. Our stance is neutral with a positive bias, contingent on cash-flow evidence.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenure / backgroundAge (born)Disclosed compensation (latest available)

Dr Che Fengsheng

Co-founder, Executive Chairman

Founder since 2001; previously Executive Chairman and CEO at SGX listing; Master of Medicine (Neurology), EMBA

1,962

CNY7.00m (Simply Wall St)

Dr Guo Weicheng

Deputy Chairman and CEO

CEO since 20 Oct 2014; co-founding executive (Executive Deputy Chairman at SGX listing); Master of Medicine (General Surgery)

1,964

CNY3.00m, 100% salary (Simply Wall St)

Ms Miao Guili

Executive Director, Deputy CEO, CFO, Chief Investment Officer

—1,974—

Dr Zhang Jionglong

Executive Director

Long-serving director (non-executive at SGX listing)

1,962

CNY0.65m (Simply Wall St)

Ms Chen Yanling

Executive Director, Joint Company Secretary

—1,979

CNY1.77m (Simply Wall St)

Mr Tsang Wah Kwong

Independent Non-executive Director; Audit Committee chair

Appointed 4 Sep 2013

—

CNY0.37m

Dr Zhu Xun

Independent Non-executive Director; Remuneration Committee chair

Appointed 20 Feb 2014

—

CNY0.37m

Mr Wang Guan

Independent Non-executive Director; Nomination Committee chair

Appointed 2023

—

CNY0.20m

Mr Li Kin Wai

Joint Company Secretary

—1,989—

Mr Meng Xianhui

Deputy General Manager

Former executive director at SGX listing

1,964—

Major Shareholders

HolderStakeSource / note

Dr Che Fengsheng

5.44% (direct, per aggregator)

—

Dr Zhang Jionglong

2.18%

Simply Wall St

Dr Guo Weicheng

0.12%

Simply Wall St

Insiders (aggregate)

7.85%

StockAnalysis (Aug 2026)

Institutions (aggregate)

6.53%

StockAnalysis (Aug 2026)

Free float

Approx. 3.69bn shares of 9.02bn (41%)

StockAnalysis — implies roughly 59% held by strategic/connected holders

Treasury shares

334.2m (3.6% of issued)

2026 Interim Results

Competitive Landscape

Competitors by Segment

SegmentCompetitorOverlapNote

Aesthetics — toxins

AbbVie / Allergan Aesthetics (Botox)

Premium imported toxin

Historically about half of China's legal toxin market (2019, ChemLinked)

Aesthetics — toxins

Lanzhou Institute of Biological Products (Hengli / CBTX-A)

Domestic value toxin

About 47% share in 2019 (ChemLinked)

Aesthetics — toxins

Ipsen / Galderma (Dysport)

Imported toxin

Approved in China in 2020

Aesthetics — toxins

Imeik Technology (300896.SZ)

Toxin approved Jan 2026; HA, PLLA and regenerative fillers

Largest domestic injectables player

Aesthetics — toxins

Huadong Medicine / Sinclair (000963.SZ)

Ellansé PCL filler; Retoxin toxin approved 2026

Direct PCL competitor to Qingyan

Aesthetics — HA / biomaterials

Bloomage Biotechnology (688363.SH)

HA fillers and skin boosters

—

Aesthetics — regenerative

Changchun Shengboma and other PLLA makers

PLLA fillers

—

Aesthetics — devices

Solta (Thermage) and other RF microneedle brands

Optoelectronic

Sihuan distributes a Thermage-type device itself

Oncology — CDK4/6

Pfizer (palbociclib), Novartis (ribociclib), Lilly (abemaciclib), Hengrui (dalpiciclib)

Bireociclib

Entrenched incumbents with NRDL coverage

Oncology — ALK

Roche (alectinib), Pfizer (lorlatinib), Betta (ensartinib)

Dirozalkib

Crowded first-line ALK market

Digestive — PPI/P-CAB

Generic PPIs; P-CABs (vonoprazan, tegoprazan, keverprazan)

Anaprazole

P-CAB substitution risk

Diabetes / GLP-1

Novo Nordisk; Hengrui (henagliflozin); Gan & Lee; Tonghua Dongbao (partner); multiple semaglutide biosimilar developers

Huisheng

Semaglutide biosimilar race is crowded

Generics

CSPC, Sino Biopharm, Luye Pharma and many VBP bidders

CCV, anti-infective

Price-driven competition

Peer Comparison FY2025

MetricSihuan FY2025Imeik FY2025Huadong Medicine FY2025Huadong aesthetics segment FY2025

Revenue (CNY Mn)

2,6182,45343,6121,800

Revenue growth (%)

37.7-18.94.1-21.5

Net profit attributable (CNY Mn)

179.71,2913,414—

Net margin (%)

6.952.67.8—

R&D intensity (%)

11.110.0——

Company Snapshot

$364.1M

Revenue

2,843

Employees

$830M

Market Cap

2001

Founded

Wan Chai, Hong Kong

Headquarters

SWOT Analysis

Strengths

  • Profit engine with high margins: medical aesthetics delivered FY2025 segment profit of RMB818.4m on revenue of RMB1,485.3m (55.1% margin; gross margin 79.5%) (FY2025 Results).
  • Counter-cyclical share gains: aesthetics revenue +99.6% in FY2025 versus Imeik -18.9% and Huadong aesthetics -21.5% (FY2025 Results; Longbridge; 10jqka).
  • Channel breadth: 9,000+ cooperating institutions, all top-500 institutions, 350+ strategic agreements (2026 Interim Results).
  • Balance-sheet capacity: RMB4,018.2m of cash and liquid investments vs RMB915.6m of borrowings at 30 Jun 2026 (2026 Interim Results).
  • Differentiated oncology data: BRIGHT-2 mPFS 17.5 vs 7.3 months (HR 0.47); DIAMOND-2 mPFS 31.3 vs 12.9 months, IC-ORR 91.7% (2026 Interim Results).
  • Value crystallisation capability: Xuanzhu IPO raised HK$781m with 4,908x retail oversubscription, released redemption liabilities and cut finance costs 34% in H1 2026 (etnet; 2026 Interim Results).

Weaknesses

  • Cash conversion: FY2025 operating cash flow of RMB-23.6m despite profit; receivables up 95% (S&P).
  • Customer concentration: one customer group equal to 27.8% of FY2025 revenue (RMB728.5m) (FY2025 Results).
  • Tax inefficiency: effective tax rate of 55.6% in FY2025, with RMB181.2m tax effect from unrecognised losses (FY2025 Results).
  • Generic collapse: H1 2026 generic revenue -58.9% and segment loss of RMB74.1m (2026 Interim Results).
  • Earnings quality: H1 2026 profit relied on a RMB154.2m disposal gain and RMB110.7m associate profit (2026 Interim Results).
  • Governance legacy: 2015 accounting investigation revised FY2013 revenue down approx. 45% and suspended trading for about a year (GMT Research); two INEDs with tenure over nine years.

Opportunities

  • Regenerative scale-up: PLLA terminal volume in the industry's first tier in H1 2026; six new specifications approved (2026 Interim Results).
  • GLP-1 entry: semaglutide diabetes approval expected early 2027; obesity NDA in Q4 2026 (2026 Interim Results).
  • Out-licensing: Boston Oncology MENA deal (>US$100m potential) as a template for XZP-7797 and other assets (2026 Interim Results).
  • Minority buy-in: raising Meiyan Space from 90% to 100% would lift attributable profit (2026 Interim Results).
  • Huisheng capitalisation: a possible listing could crystallise value and remove remaining redemption liabilities (FY2025 Results).
  • Globalisation: EU registrations via Suisselle; Huisheng insulin into 15 countries; Sylfirm X FDA/KFDA certification (FY2025 and 2026 Interim Results).

Threats

  • Toxin competition: Imeik toxin approval (Jan 2026) and Huadong's Retoxin approval (2026) (MarketScreener; FilingReader).
  • Aesthetics demand downturn: peers' revenue declines and Sihuan's own deceleration to +18.5% in H1 2026 (2026 Interim Results).
  • Hugel dependency: Letybo® is manufactured by Hugel; any change in the relationship would hit the core traffic product (HKEX 27 Sep 2024).
  • NRDL and pricing pressure: innovative drugs depend on NRDL access and negotiated price cuts (FY2025 Results).
  • Further VBP rounds: generic price erosion and the 2027 insulin VBP cycle (moomoo citing VBP cycle).
  • Crowded GLP-1 biosimilar field: many domestic semaglutide entrants after patent expiry (industry context).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025Huiyanzhen and Sifuyan (PLLA) approved FY2025 ResultsEntry into regenerative fillers with self-developed products
May 2025Bireociclib approved (two indications) FY2025 ResultsFirst oncology innovative drug approval for Xuanzhu
6 Jun 2025AGM grants repurchase mandate HKEX 17 Jun 2025Basis for 2025–2026 buybacks
17 Jun 2025Buyback execution under HK$500m programme HKEX 17 Jun 2025Capital return
Jul 2025Simultaneous launch of Qingyan, Huiyanzhen, Sifuyan; first Bireociclib launch FY2025 ResultsCommercial inflection in aesthetics
Aug 2025Dirozalkib approved; Semaglutide (diabetes) NDA accepted FY2025 ResultsPipeline delivery
29 Aug 2025H1 2025 results: revenue +20.7%, attributable profit RMB102.6m; interim DPS RMB0.99 cents 2025 Interim ResultsReturn to profit
30 Sep 2025Dongyan skin booster approval announced HKEX 30 Sep 2025Fills booster category gap
15 Oct 2025Xuanzhu Biopharm lists on HKEX; repurchase of 10m Sihuan shares at HK$1.5189 Fangda; HKEX 15 Oct 2025Value crystallisation; peak Xuanzhu value over HK$30bn
Nov 2025Dongyan commercial launch FY2025 ResultsNew growth SKU
Dec 2025Bireociclib added to NRDL; Anaprazole NRDL renewed at unchanged price; XZP-7797 Ph I begins FY2025 ResultsReimbursement access
29 Dec 2025Voluntary buyback announcement citing completed Suisselle investment HKEX 29 Dec 2025Globalisation signal
Jan 2026Six additional PLLA specifications approved FY2025 ResultsGraduated dosing to defend pricing
10 Feb 2026Positive profit alert: FY2025 revenue at least RMB2.5bn, net profit at least RMB150m Tiger BrokersPre-announcement of turnaround
14 Feb 2026Huisheng licenses Hui You Jia and Hui You Da to Tonghua Dongbao FY2025 ResultsShift to partner commercialisation
Mar 2026Bireociclib first-line indication approved FY2025 ResultsFull treatment-course coverage
31 Mar 2026FY2025 results; final DPS RMB0.96 cents FY2025 ResultsConfirms turnaround
1–2 Apr 2026Strategic partnership with Biocytogen Business WireAI/antibody pipeline for weight loss
H1 2026AACR 2026 oral presentation of DIAMOND-2; BRIGHT-2 final analysis published in JAMA Oncology 2026 Interim ResultsClinical validation
H1 2026Anaprazole reflux esophagitis NDA accepted; H. pylori Ph III first patient dosed 2026 Interim ResultsIndication expansion
H1 2026Xuanzhu–Boston Oncology MENA licence (>US$100m potential) 2026 Interim ResultsFirst large out-licence
H1 2026Xuanzhu included in Hang Seng Composite Index and Stock Connect 2026 Interim ResultsLiquidity for subsidiary
H1 2026Meiyan Space stake raised to 90%; subsidiary disposal gain RMB154.2m 2026 Interim ResultsProfit attribution and portfolio pruning
H1 202646m shares repurchased; employee share award scheme 2026 Interim ResultsCapital return
30 Jun 2026Ex-dividend date for FY2025 final dividend StockAnalysisShareholder return
27 Jul 2026Positive profit alert for H1 2026 HKEX 27 Jul 2026Pre-announcement
26 Aug 2026H1 2026 results: revenue +1.3%, attributable profit +119% to RMB224.7m; generic revenue -58.9%; no interim dividend 2026 Interim ResultsGrowth deceleration; one-off-aided profit
27 Aug 2026Repurchase of 10m shares at HK$0.8111 average Tiger BrokersBuyback at half the October 2025 price
Oct 2026Share price at HK$0.72 (2 Oct), roughly 53% below October 2025 repurchase price StockAnalysisMarket scepticism

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Revenue fell from CNY 3,038 Mn in FY2021 to CNY 2,618 Mn in FY2025.
Sihuan Pharmaceutical Holdings Group Ltd. — Income Statement: Revenue & Gross Profit
Series (CNY Mn)FY2021FY2022FY2023FY2024FY2025
Revenue3,0382,1811,8611,9012,618
Gross profit2,4301,4881,2961,2421,802

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Sihuan Pharmaceutical — Annual Results Announcement FY2025 (HKEX, 31 Mar 2026) (www1.hkexnews.hk)
  2. Sihuan Pharmaceutical — Interim Results Announcement H1 2026 (HKEX, 26 Aug 2026) (www1.hkexnews.hk)
  3. Sihuan Pharmaceutical — Interim Results Announcement H1 2025 (HKEX, 29 Aug 2025) (www1.hkexnews.hk)
  4. Sihuan Pharmaceutical — FY2024 Annual Results (HKEX, 28 Mar 2025) (www1.hkexnews.hk)
  5. Sihuan Pharmaceutical — FY2023 Annual Results (HKEX, 28 Mar 2024) (www1.hkexnews.hk)
  6. Sihuan Pharmaceutical — FY2022 Annual Results (HKEX, 24 Mar 2023) (www1.hkexnews.hk)
  7. Sihuan Pharmaceutical — FY2021 Annual Results (HKEX, 29 Mar 2022) (www1.hkexnews.hk)
  8. Sihuan Pharmaceutical — 2019 Interim Results (goodwill impairment) (www1.hkexnews.hk)
  9. Sihuan Pharmaceutical — FY2018 Annual Results (www1.hkexnews.hk)
  10. Sihuan Pharmaceutical — Annual Reports 2010, 2011, 2013, 2020 (HKEX); Annual Reports 2007, 2008 (NUS library archive)
  11. HKEX announcements: Letybo® renewal (27 Sep 2024); Dongyan approval (30 Sep 2025); share repurchases (17 Jun 2025, 15 Oct 2025, 29 Dec 2025); Huisheng Series A (1 Jun 2022) and A+ (3 Jan 2023); list of directors (17 Oct 2022; 31 Mar 2023); positive profit alert (27 Jul 2026); profit warning (2 Aug 2023)
  12. StockAnalysis.com (S&P Global Market Intelligence data): income statement, balance sheet, cash flow, statistics for HKG:0460
  13. Quartr event summaries: Sihuan H1 2025, H2 2025, H1 2026; Imeik Q2 2026; Huadong Q4 2025
  14. Tiger Brokers / Bulletin Express: FY2025 positive profit alert (Feb 2026); H1 2025 results; Aug 2026 buyback
  15. Webull / Zhitong Finance: H1 2026 results summary
  16. Bamboo Works: Sihuan key monitoring catalogue and aesthetics pivot; Xuanzhu IPO brief
  17. GMT Research: Sihuan accounting history profile
  18. ThePharmaLetter; Fangda Partners; IPOX; etnet: Xuanzhu Biopharm IPO details
  19. Business Wire / BioSpace: Biocytogen–Sihuan strategic partnership (Apr 2026)
  20. Simply Wall St; Yahoo Finance; GlobalData: management, compensation, ownership data
  21. Longbridge; dcf-analysis; MarketScreener: Imeik financials and toxin approval
  22. 10jqka; FilingReader: Huadong Medicine FY2025 results
  23. ChemLinked; Korea Times; GII/QYResearch: botulinum toxin market context

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.